Log In
BCIQ
Print this Print this
 

AF-220

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionSecond generation purinergic receptor P2X ligand-gated ion channel 3 (P2X3) receptor antagonist
Molecular Target Purinergic receptor P2X ligand-gated ion channel 3 (P2X3)
Mechanism of ActionP2RX3 antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationMigraine
Indication DetailsTreat migraine
Regulatory Designation
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,250.0M

$500.0M

$750.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/27/2016

$1,250.0M

$500.0M

$750.0M

12/21/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today